香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 二零二五年八月二十二日舉行之股東週年大會 投票表決結果 茲提述精優藥業控股有限公司（「本公司」）日期為二零二五年七月二十九日之通函及股東週 年大會（「股東週年大會」）通告（「該通告」）。 股東週年大會投票表決結果 本公司董事會（「董事會」）宣佈，於二零二五年八月二十二日舉行之股東週年大會上，載於 該通告所有提呈之決議案（「決議案」）均經本公司之股東（「股東」）以投票表決方式獲正式通 過。 於股東週年大會當日，本公司已發行股份（「股份」）總數為2,390,000,000股，此為賦予股東權 利出席股東週年大會並於會上表決贊成或反對決議案的股份總數。概無任何股份給予股東 權利出席股東週年大會但根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.40 條所載須放棄表決贊成決議案。概無任何股東於股東週年大會上須根據上市規則之規定放 棄表決權。 ...

Group 1 - The stock price of Jingyou Pharmaceutical (00858) increased by 20.34% on August 15, reaching HKD 0.142 per share with a trading volume of HKD 6.8024 million [1] - Jingyou Pharmaceutical Holdings Limited primarily promotes and sells pharmaceutical products in the Chinese market, develops gene-related technologies, and works on oral insulin products through joint ventures [1] - The company is listed on the main board of the Hong Kong Stock Exchange and is registered in Bermuda [1] Group 2 - As of the 2024 annual report, Jingyou Pharmaceutical reported total revenue of HKD 51.1515 million and a net profit of HKD 205 million [2]

Group 1 - The core point of the news is that 精优药业 (Jingyou Pharmaceutical) experienced a significant stock price increase of 13.56%, reaching HKD 0.134, with a trading volume of HKD 2.323 million [1] - The company has entered into three subscription agreements on August 14, 2025, with different investors, agreeing to issue a total of 136 million shares at a subscription price of HKD 0.097 per share [1] - The total amounts for the subscription agreements are HKD 291 million for the first agreement, HKD 194 million for the second, and HKD 1.067 billion for the third [1] Group 2 - The net proceeds from the subscription agreements will be used for the potential new business development in health products, equipment, and technology trade, manufacturing, sales, and distribution in China [2] - The company aims to expand its health-related business opportunities into overseas markets while continuing to utilize its existing internal cash resources to maintain and develop its current pharmaceutical business [2]

Group 1 - The stock of Jingyou Pharmaceutical (00858) surged over 13%, reaching a price of 0.134 HKD with a trading volume of 2.323 million HKD [1] - The company announced three subscription agreements on August 14, 2025, with different investors, agreeing to issue a total of 136 million shares at a subscription price of 0.097 HKD per share [1] - The total amounts for the subscription agreements are 2.91 million HKD, 1.94 million HKD, and 10.67 million HKD respectively for the three agreements [1] Group 2 - The net proceeds from the subscription will be used for potential new business development in health products, equipment, and technology trade, manufacturing, sales, and distribution in China [2] - The company aims to expand its health-related business opportunities into overseas markets while continuing to utilize its existing cash resources to maintain and develop its current pharmaceutical business [2]

Group 1 - The stock of Jingyou Pharmaceutical (00858) surged over 13%, reaching a price of 0.134 HKD with a trading volume of 2.323 million HKD [1] - The company entered into subscription agreements with three different parties on August 14, 2025, for a total of 300 million HKD in new shares at a price of 0.097 HKD per share [1][2] - The total amount from the subscription agreements is 2.91 million HKD, 1.94 million HKD, and 10.67 million HKD respectively, with conditions that must be met for the agreements to be finalized [1][2] Group 2 - The net proceeds from the subscription agreements will be used for the development of new business opportunities in health products, equipment, and technology trade in China, as well as expanding into overseas markets [2] - The company will continue to utilize its existing cash resources to maintain and develop its current pharmaceutical business [2]

Group 1 - The company has entered into subscription agreements with three subscribers to issue a total of 160 million shares at a subscription price of HKD 0.097 per share, raising a total of HKD 2.91 million, HKD 1.94 million, and HKD 10.67 million respectively [2] - The net proceeds from the subscription will be used to support the group's potential new business development in the trade, manufacturing, sales, and distribution of health products, equipment, and technology in China, as well as to expand into overseas health-related business opportunities [2] - The company plans to continue using internal cash resources to maintain and develop its existing pharmaceutical business, believing that factors such as an aging population, increasing chronic diseases, heightened health awareness, and technological advancements will sustain the demand for health and patient care products and solutions in the healthcare industry [2]

Group 1 - The core point of the news is that 精优药业 announced a new share issuance to raise approximately 15.52 million HKD for potential business development in health products and related opportunities [1][2] - The company issued a total of 160 million shares to three different subscribers, with the share price set at 0.097 HKD, representing a discount of about 17.8% from the closing price on August 14, 2025 [1] - The funds raised will be used for the development of health products, equipment, and technology trade, as well as sales and distribution in China and potential overseas markets [2] Group 2 - The issuance is based on a general authorization granted by the shareholders' meeting, and the completion of the subscriptions is subject to certain conditions [2] - The shares issued to each subscriber represent a small percentage of the existing and enlarged share capital, with Subscriber I accounting for approximately 1.26% of the existing capital and 1.24% of the enlarged capital [1] - The completion of the subscriptions is expected to occur within 7 business days after the conditions are met [2]

Group 1 - The company has entered into three subscription agreements with different subscribers, agreeing to issue a total of 1.43 billion shares at a subscription price of HKD 0.097 per share, raising a total of HKD 1.55 billion [1][2] - The first agreement involves the issuance of 30 million shares for a total of HKD 2.91 million, the second agreement involves 20 million shares for HKD 1.94 million, and the third agreement involves 110 million shares for HKD 10.67 million [1] - The subscription matters are conditional and will only be finalized upon the fulfillment of specified conditions [1] Group 2 - The net proceeds from the subscription will be used to develop potential new business in health products, equipment, and technology trade, manufacturing, sales, and distribution in China, as well as to expand related business opportunities overseas [2] - The company believes that the demand for products and solutions that improve health and patient care will continue to grow due to factors such as an aging population, increasing prevalence of chronic diseases, heightened health awareness, and technological advancements [2] - The net proceeds will support the company in seizing new business opportunities more effectively [2]

Core Viewpoint - The company, 精优药业, has entered into subscription agreements with three parties to issue new shares at a price of HKD 0.097 per share, which represents a discount to the market price on the date of the agreements [1][2][3] Group 1: Subscription Agreements - The company has signed Subscription Agreement I with subscriber I (曾广钊) to issue 30 million shares, representing approximately 1.26% of the existing issued share capital [1] - Subscription Agreement II was signed with subscriber II (张晓佳) for 20 million shares, equivalent to about 0.84% of the existing issued share capital [1] - Subscription Agreement III was established with subscriber III (Fudan Health International Ltd.) for 110 million shares, accounting for approximately 4.6% of the existing issued share capital [2] Group 2: Financial Implications - If all shares from Subscription Agreement I are successfully issued, the total proceeds will be approximately HKD 2.91 million, with a net amount of about HKD 2.89 million [3] - For Subscription Agreement II, the total proceeds are expected to be around HKD 1.94 million, with a net amount of approximately HKD 1.93 million [3] - The proceeds from Subscription Agreement III are projected to total about HKD 10.67 million, with a net amount of approximately HKD 10.60 million [3] Group 3: Use of Proceeds - The net proceeds from the subscriptions will be utilized for potential new business development in health products, equipment, and technology trade, manufacturing, sales, and distribution in China [3] - The company aims to expand its health-related business opportunities into overseas markets while continuing to maintain and develop its existing pharmaceutical business through internal cash resources [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 根據一般授權發行新股份 認購協議I 於二零二五年八月十四日（ 交易時段後 ），本公司與認購方I訂立認購協議I，據此，認購 方I已有條件同意認購，而本公司已有條件同意按認購價（I 總金額為2,910,000港元，相等 於每股認購股份I 0.097港元）配發及發行合共30,000,000股認購股份I。根據認購協議I進行 之認購事項I須待條件I達成後方可作實。 根據認購事項 I將予配發及發 行之認購股份I 相當於(i)於 本公告日期本公司 現有已發行股 本約1.26%；及(ii)經配發及發行認購股份I擴大之本公司已發行股本約1.24%（ 假設本公司 已發行股本於本公告日期至完成I期間將不會有任何變動，且並無計及本公司根據認購事 項II可能配發及發行之認購股份II以及本公司根據認購事 ...